Clinical Trial Update: Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of bortezomib in adults with relapsed or refractory Hodgkin lymphoma has completed enrollment and the trial status is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma | Phase 2 | Status: COMPLETED